APA (7th ed.) Citation

T, D., I, M., D, G., & S, E. (2020). The ethics of innovation for Alzheimer's disease: The risk of overstating evidence for metabolic enhancement protocols. Theoretical medicine and bioethics, 41(5-6), 223. https://doi.org/10.1007/s11017-020-09536-7

Chicago Style (17th ed.) Citation

T, Daly, Mastroleo I, Gorski D, and Epelbaum S. "The Ethics of Innovation for Alzheimer's Disease: The Risk of Overstating Evidence for Metabolic Enhancement Protocols." Theoretical Medicine and Bioethics 41, no. 5-6 (2020): 223. https://doi.org/10.1007/s11017-020-09536-7.

MLA (9th ed.) Citation

T, Daly, et al. "The Ethics of Innovation for Alzheimer's Disease: The Risk of Overstating Evidence for Metabolic Enhancement Protocols." Theoretical Medicine and Bioethics, vol. 41, no. 5-6, 2020, p. 223, https://doi.org/10.1007/s11017-020-09536-7.